A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sobosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection - GS-US-342-1521
Phase of Trial: Phase III
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 21 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 21 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.